Pfizer Licensing Agreement Renewal

AI SummaryClose X

Trellus Health plc has renewed its Licensing Agreement with Pfizer Inc. to continue licensing patient support educational content for Pfizer's inflammatory bowel disease digital application. This renewal, following an initial agreement in Q2 2024, underscores user engagement and the value of Trellus Health's resilience-driven approach. The company has reduced its monthly cash burn to approximately $300k as of March 2026, and with this agreement and a loan, expects its cash runway to extend into May 2026, while actively pursuing further funding options.

Disclaimer*

UK 100

Latest directors dealings